Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROTECT: Pazopanib in Adjuvant RCC
NCT01235962Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2010
- Primary completion
- Oct 2015
- Modality
- Small Molecules
- Countries
- 26
01
Overview
Phase 3, randomised, double-blind trial in renal cell carcinoma (RCC) comparing Pazopanib Arm with Placebo Arm (2 arms). Primary endpoint: Disease-free Survival at 5 years. Started Nov 2010; status: completed.
02
Drugs
pazopanib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT01235962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01235962.